Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 11.27
- Piotroski Score 1.00
- Grade Buy
- Symbol (ANIX)
- Company Anixa Biosciences, Inc.
- Price $3.19
- Changes Percentage (4.23%)
- Change $0.13
- Day Low $3.18
- Day High $3.64
- Year High $5.13
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 01/01/2025
- Fiscal Year End N/A
- Average Stock Price Target $7.50
- High Stock Price Target $8.00
- Low Stock Price Target $7.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.37
- Trailing P/E Ratio -6.89
- Forward P/E Ratio -6.89
- P/E Growth -6.89
- Net Income $-9,811,000
Income Statement
Quarterly
Annual
Latest News of ANIX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Nutanix Stock Sees RS Rating Jump To 81
IBD's RS Rating assesses stock market leadership on a scale of 1 to 99 based on price performance over the past year. Successful stocks often start with an RS Rating above 80. Nutanix stock is forming...
By Investor's Business Daily | 1 month ago -
Stocks To Watch: Nutanix Cl A Sees RS Rating Jump To 81
Learn how to trade options effectively by choosing the right strategy for best results. IBD's RS Rating indicates market leadership on a scale of 1 to 99, with stocks over 80 often being top performer...
By Investor's Business Daily | 1 month ago -
Generation Investment Management Global Equity Strategy's Investment Thesis on Nutanix (NTNX)
Generation Investment Management's recent investor letter discussed the underperformance of its Global Equity Strategy, attributing it to factors like not owning Nvidia. Nutanix, Inc. was highlighted ...
By Yahoo! Finance | 1 month ago
